Drug Profile
Research programme: influenza virus vaccine intranasal - Shin Nippon Biomedical Laboratories
Alternative Names: TR-FluLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Shin Nippon Biomedical Laboratories
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in Japan (Intranasal, Powder)
- 12 May 2010 Preclinical trials in Influenza virus infections in Japan (Intranasal)
- 12 May 2010 Immunogenicity data from a Preclinical trial in Influenza virus infections released by Shin Nippon Biomedical Laboratories